StockNews.com initiated coverage on shares of DBV Technologies (NASDAQ:DBVT - Free Report) in a report published on Tuesday morning. The firm issued a hold rating on the stock.
A number of other equities analysts also recently commented on DBVT. HC Wainwright boosted their target price on shares of DBV Technologies from $25.00 to $35.00 and gave the stock a "buy" rating in a report on Thursday, October 24th. JMP Securities reaffirmed a "market outperform" rating and issued a $10.00 price objective on shares of DBV Technologies in a research report on Tuesday, December 10th.
Read Our Latest Stock Report on DBVT
DBV Technologies Stock Down 7.9 %
DBVT stock traded down $0.26 during trading on Tuesday, hitting $3.04. 31,495 shares of the company's stock traded hands, compared to its average volume of 71,535. The firm has a market capitalization of $62.53 million, a P/E ratio of -0.68 and a beta of 0.64. DBV Technologies has a 1 year low of $2.20 and a 1 year high of $10.70. The business has a fifty day simple moving average of $3.42 and a two-hundred day simple moving average of $3.97.
About DBV Technologies
(
Get Free Report)
DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.
See Also
Before you consider DBV Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DBV Technologies wasn't on the list.
While DBV Technologies currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for January 2025. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
